Comstock (NYSE:LODE) and Cyclo Therapeutics (NASDAQ:CYTH) Head to Head Review
Comstock (NYSE:LODE) and Cyclo Therapeutics (NASDAQ:CYTH) Head to Head Review
Comstock (NYSE:LODE – Get Rating) and Cyclo Therapeutics (NASDAQ:CYTH – Get Rating) are both small-cap basic materials companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.
康斯托克(紐約證券交易所代碼：LODE-GET)和循環治療公司(納斯達克：CYTH-GET評級)都是小盤股基礎材料公司，但哪一項投資更具優勢？我們將根據這兩家公司的收益、風險、機構所有權、盈利能力、分析師建議、估值和股息等方面的實力進行比較。
Volatility & Risk
波動性與風險
Comstock has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.5, suggesting that its share price is 150% less volatile than the S&P 500.
Comstock的貝塔係數為1.68，這表明其股價的波動性比標準普爾500指數高68%。相比之下，Cyclo Treateutics的貝塔係數為-0.5，這表明其股價的波動性比標準普爾500指數低150%。
Profitability
盈利能力
This table compares Comstock and Cyclo Therapeutics' net margins, return on equity and return on assets.
此表比較了Comstock和Cyclo治療公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Comstock | -7,762.50% | -25.38% | -17.24% |
| Cyclo Therapeutics | -747.63% | -120.38% | -95.12% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 康斯托克 | -7,762.50% | -25.38% | -17.24% |
| Cycle治療公司 | -747.63% | -120.38% | -95.12% |
Valuation & Earnings
估值與收益
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Comstock | $860,000.00 | 36.72 | -$24.58 million | ($0.68) | -0.54 |
| Cyclo Therapeutics | $1.59 million | 5.97 | -$14.29 million | ($1.58) | -0.71 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 康斯托克 | $860,000.00 | 36.72 | -2,458萬元 | ($0.68) | -0.54 |
| Cycle治療公司 | 159萬美元 | 5.97 | -1,429萬元 | ($1.58) | -0.71 |
Cyclo Therapeutics has higher revenue and earnings than Comstock. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Comstock, indicating that it is currently the more affordable of the two stocks.
Cycle治療公司的收入和收益比康斯托克公司高。Cycle治療公司的市盈率低於Comstock，這表明它目前是兩隻股票中更負擔得起的一隻。
Institutional and Insider Ownership
機構和內部人持股
6.0% of Comstock shares are owned by institutional investors. Comparatively, 4.8% of Cyclo Therapeutics shares are owned by institutional investors. 16.4% of Comstock shares are owned by insiders. Comparatively, 12.0% of Cyclo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
康斯托克6.0%的股份由機構投資者持有。相比之下，機構投資者持有Cyclo Treateutics 4.8%的股份。康斯托克16.4%的股份由內部人士持有。相比之下，Cyclo治療公司12.0%的股份由內部人士持有。強大的機構持股表明，捐贈基金、大型基金管理公司和對衝基金相信，一家公司的長期表現將好於大盤。
Analyst Ratings
分析師評級
This is a summary of current ratings and recommmendations for Comstock and Cyclo Therapeutics, as reported by MarketBeat.
這是MarketBeat報道的Comstock和Cyclo治療公司目前的評級和推薦摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Comstock | 0 | 0 | 0 | 0 | N/A |
| Cyclo Therapeutics | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 康斯托克 | 0 | 0 | 0 | 0 | 不適用 |
| Cycle治療公司 | 0 | 0 | 0 | 0 | 不適用 |
Summary
摘要
Comstock beats Cyclo Therapeutics on 8 of the 11 factors compared between the two stocks.
Comstock在兩隻股票之間比較的11個因素中有8個擊敗了Cyclo Treeutics。
About Comstock
康斯托克公司簡介
(Get Rating)
(獲取評級)
Comstock Inc. engages in the exploration, development, and production of mineral properties in Nevada. The company explores for gold, silver, lithium, nickel, cobalt, and mercury ores. It operates in two segments, Mining and Real Estate. The Mining segment owns and controls approximately 9,358 acres of mining claims and parcels, including approximately 2,396 acres of patented claims and surface parcels; and approximately 6,962 acres of unpatented mining claims in the Comstock and Silver City districts, as well as focuses on exploring and developing properties in the Lucerne and Dayton resource areas; and Occidental and Gold Hill mineral properties. The Real Estate segment comprises land and real estate rental properties, as well as the Gold Hill Hotel and Daney Ranch properties. It has collaboration agreements with Oro Industries Inc. and Mercury Clean Up, LLC for the manufacture and deployment of mercury remediation systems with proprietary mechanical, hydro, electro-chemical, and oxidation processes to reclaim and remediate mercury from soils, waste, and tailings. The company was formerly known as Comstock Mining Inc. and changed its name to Comstock Inc. in May 2022. Comstock Inc. was incorporated in 2008 and is based in Virginia City, Nevada.
康斯托克公司在內華達州從事礦產資源的勘探、開發和生產。該公司勘探金、銀、鋰、鎳、鈷和汞礦石。它分為兩個部門，礦業和房地產。礦業部門擁有及控制約9,358英畝採礦權及地塊，包括約2,396英畝有專利權的礦權及地表地塊；以及康斯托克及銀城地區約6,962英畝的非專利礦業權，並專注於勘探及開發盧塞恩及代頓資源區的礦產；以及西方及Gold Hill礦產。房地產部門包括土地和房地產租賃物業，以及金山酒店和丹尼牧場物業。該公司與Oro Industries Inc.和Merht Clean Up，LLC簽署了合作協議，製造和部署汞修復系統，該系統採用專有的機械、水力、電化學和氧化工藝，以回收和修復土壤、廢物和尾礦中的汞。該公司前身為Comstock Mining Inc.，並於2022年5月更名為Comstock Inc.。康斯托克公司成立於2008年，總部設在內華達州弗吉尼亞州。
About Cyclo Therapeutics
關於Cyclo治療
(Get Rating)
(獲取評級)
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Cyclo治療公司是一家臨牀階段生物技術公司，開發以環糊精為基礎的產品，用於治療各種疾病。它的主要候選藥物是Trappsol Cyclo，這是一種孤兒藥物，是治療Niemann-Pick C型疾病的第三階段臨牀試驗。該公司還開發了用於治療阿爾茨海默病的Trappsol Cyclo。此外，它還向製藥、營養和其他行業銷售環糊精和相關產品，主要用於診斷和特殊藥物。該公司前身為CTD控股公司，並於2019年9月更名為Cyclo治療公司。Cyclo治療公司成立於1990年，總部設在佛羅裏達州蓋恩斯維爾。
Receive News & Ratings for Comstock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comstock and related companies with MarketBeat.com's FREE daily email newsletter.
接受Comstock Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Comstock和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。